Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885524 | 0.82 | KDM4E (0.34) | KDM4ELMNA | |
| SCHEMBL28041254 | 0.81 | MEN1 (0.33) | — | |
| SCHEMBL442844 | 0.78 | — | — | |
| SCHEMBL6211887 | 0.77 | TSHR (0.50) | KDM4EALDH1A1LMNA | |
| SCHEMBL22721430 | 0.76 | DHODH (0.41) | ALOX5KDM4EALDH1A1 | |
| SCHEMBL11859852 | 0.76 | KDM4E (0.34) | ALOX5KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4887608 | 0.74 | L3MBTL1 (0.45) | KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL4888320 | 0.74 | NR1I2 (0.32) | — | |
| SCHEMBL3332936 | 0.73 | PNMT (0.31) | — | |
| SCHEMBL6507641 | 0.72 | IDO1 (0.57) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293939-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS | CULSHAW ANDREW JAMES | 2008-11-27 | — | — | US | disclosed |
| CN-100432059-C | Quinazolinone derivatives useful as anti-hyperalgesic agents | NOVARTIS AG (CH) | 2008-11-12 | — | — | CN | disclosed |
| US-20060154942-A1 | Quinazolinone derivatives useful as anti-hyperalgesic agents | CULSHAW ANDREW J | 2006-07-13 | — | — | US | disclosed |
| CN-1711249-A | Quinazolinone derivatives useful as anti-hyperalgesic agents | NOVARTIS AG (CH) | 2005-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293939-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS | OPRK1, OPRL1, TRPV1 | ALOX5 1069/4885P2RX7 50/4885KDM4E 3327/4885 |
| US-20060154942-A1 | Quinazolinone derivatives useful as anti-hyperalgesic agents | OPRK1, OPRL1, TRPV1 | ALOX5 1069/4885P2RX7 50/4885KDM4E 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.